Patents Represented by Attorney, Agent or Law Firm Dianne M. Rees
-
Patent number: 6777448Abstract: Micellar non-aqueous or aqueous compositions for the therapeutic treatment of animal diseases caused by parasitic worms or nematodes, comprising rafoxanide and specific combinations of solvents which act as stabilising and absorption promoting agents. The solvents are selected from non-ionic surface-active agents such as Tween®-80 and from N-methylpyrrolidone, 2-pyrrolidone or dimethylsulfoxide. The compositions are easy to prepare, stable upon storage and can be administered orally, by injection or topically. With these formulations, an improvement of the efficacy of rafoxanide in the treatment of the diseases is observed.Type: GrantFiled: August 29, 2002Date of Patent: August 17, 2004Assignee: New Pharma Research Sweden ABInventor: Abdul Rahman Shoa'a
-
Patent number: 6761904Abstract: The invention provides a novel pharmaceutical kit comprising a controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The controlled release composition is designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained, followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The invention also provides a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a kit.Type: GrantFiled: March 29, 2001Date of Patent: July 13, 2004Assignee: Nycomed Austria GmbHInventors: Poul Bertelsen, Annette Skinhøj, Peder Mohr Olsen
-
Patent number: 6720009Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: May 28, 2002Date of Patent: April 13, 2004Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 6709837Abstract: Disclosed are (1) a polypeptide (I) including the following amino acid sequence (II) in a molecule thereof: TyrAlaGluHisLysSerHisArgGlyGluTyrSerValCys (II) AspSerGluSerLeuTrpValThrAspLysSerSerAlaIle spIleArgGlyHisGlnValThrValLeuGlyGluIleLys ThrGlyAsnSerProValLysGlnTyrPheTyrGluThrArg CysLysGluAlaArgProValLysAsnGlyCysArgGlyIle AspAspLysHisTrpAsnSerGlnCysLysThrSerGlnThr TyrValArgAlaLeuThrSerGluAsnAsnLysLeuValGly TrpArgTrpIleArgIleAspThrSerCysValCysAlaLeu SerArgLysIleGlyArg (2) a DNA sequence coding for the polypeptide described in (1), (3) a vector including the DNA described in (2), (4) a transformant transformed by the vector described in (3), and (5) a process for producing the polypeptide (I) which comprises cultivating the transformant described in (4) in a culture medium to produce and accumulate the polypeptide described in (1) in a culture.Type: GrantFiled: March 5, 1990Date of Patent: March 23, 2004Assignee: Takeda Chemical Industries, Inc.Inventors: Kazuo Nakahama, Yoshihiko Kaisho, Koji Yoshimura, Reiko Sasada
-
Patent number: 6689807Abstract: This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.Type: GrantFiled: June 8, 2000Date of Patent: February 10, 2004Assignee: Caritas St. Elizabeth's Medical Center of Boston, Inc.Inventor: Kenneth Walsh
-
Patent number: 6682917Abstract: Because the protein of the present invention has in its amino acid sequence a homology with, for example, ribonucleotide reductase, the protein of the present invention, its DNA, antibodies to these and the like are useful in the prevention, treatment and diagnosis, etc. of cancer.Type: GrantFiled: December 28, 2001Date of Patent: January 27, 2004Assignee: Takeda Chemical Industries, LTDInventors: Yusuke Nakamura, Hirofumi Arakawa, Hiroshi Tanaka
-
Patent number: 6635440Abstract: The present invention provides a method of isolation of compounds that bind specifically to RNA or that alter the affinity of known compounds for RNA. The method utilizes changes in the levels of a fluorescent marker protein expressed in the same cell as a putative RNA-binding compound to detect those compounds of interest.Type: GrantFiled: October 23, 2000Date of Patent: October 21, 2003Assignee: European Molecular Biology LaboratoryInventors: Matthias W. Hentze, Efrosyni Paraskeva
-
Patent number: 6635434Abstract: A hapten-polymer carrier complex was found to be useful for immunoassay purposes, specifically ELISAs, for the detection of pesticides and their degradation products in hydrosoil and ground water. The degradation products of Casoron G® (also known as dichlorobenzonitrile and dichlorbenil) and Prefix® (also known as chlorthiamid and dichlorobenzthiamide) are analytes detected with high specificity and sensitivity, particularly the degradation product BAM (2,6-dichlorobenzamide). The polymer carrier complex is bound to the hapten via a linker unit, strategically positioned meta to the amide or amide derivative of BAM.Type: GrantFiled: July 21, 2000Date of Patent: October 21, 2003Assignee: Exiqon A/SInventors: Mogens Havsteen Jakobsen, Leif Bruun, Brian Pedersen
-
Patent number: 6569428Abstract: Pharmaceutical products are provided comprising EC progenitors for use in methods for regulating angiogenesis, i.e., for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting an angiogenesis modulator to specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g., anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.Type: GrantFiled: January 11, 1999Date of Patent: May 27, 2003Assignee: St. Elizabeth's Medical Center of Boston, Inc.Inventors: Jeffrey M. Isner, Takayuki Asahara
-
Patent number: 6545131Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: July 28, 2000Date of Patent: April 8, 2003Assignee: The Johns Hopkins UniversityInventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen
-
Patent number: 6531591Abstract: Quinone phosphoramidite reagents as well as photoreactive ketone phosphoramidite reagents, such as anthraquinone phosphoramidite reagents and benzophenone phosphoramidite reagents were synthesized and used for the solid phase synthesis of photoreactive-oligonucleotide conjugates. These phosphoramidite reagents are stable, suitable for large-scale synthesis and designed for automated solid phase synthesis of oligomers terminating in a photoreactive moiety.Type: GrantFiled: July 7, 2000Date of Patent: March 11, 2003Assignee: Exiqon A/SInventor: Jef Fensholdt
-
Method for electro-permeabilization of individual cellular and organellar structures and use thereof
Patent number: 6521430Abstract: The invention relates to a method for permeabilization of a cell structure consisting of a single cell, an intracellular structure or an organelle comprising the following steps: (a) microelectrodes, preferably two carbon fibre electrodes or hollow fibre electrodes, are provided, (b) the microelectrodes are connected to a power supply, (c) the electrodes, individually controlled by high-graduation micromanipulators, are placed close to the cell structure at an appropriate inter-electrode distance, and (d) a highly focused electric field of a strength sufficient to obtain electroporation is applied between the electrodes. The method may be used in order to transfer cell impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure, in biosensors, in the treatment of tumours and neurodegenerative diseases and in the study of biophysical processes.Type: GrantFiled: April 25, 2000Date of Patent: February 18, 2003Assignee: Cellectricon ABInventors: Owe Orwar, Anders Lundqvist, Peter Eriksson, Daniel Chiu -
Patent number: 6521617Abstract: New methods are provided for treating against apoptotic cell death, including apoptotic cardiac and neuronal cells. Therapies of the invention include administration of a mitochondrial oxidizer compound to a subject in need thereof, such as a subject suffering from or susceptible to stroke, heart attack, brain or spinal cord trauma, or chronic conditions that can resulting apoptotic cell death such as a neurodegenerative disease.Type: GrantFiled: October 15, 2001Date of Patent: February 18, 2003Assignee: The Johns Hopkins UniversityInventors: Eduardo Marban, Brian O'Rourke, Masaharu Akao
-
Patent number: 6511979Abstract: The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCer&bgr;1→4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.Type: GrantFiled: July 22, 1999Date of Patent: January 28, 2003Assignee: Johns Hopkins UniversityInventor: Subroto Chatterjee
-
Patent number: 6503539Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: February 26, 1999Date of Patent: January 7, 2003Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 6455303Abstract: The invention provides a method for detection of receptor- or ion channel-modulators (e.g., antagonists, blockers, etc.). The method comprises fractionating a sample by using a liquid-based separation means (e.g., such as a capillary electrophoresis device), and feeding the fractions containing the modulators directly to a biosensor. The biosensor is activatable by a receptor agonist and produces a measurable response as a result of this activation. Preferably, the agonist is fed to the biosensor through the liquid-based separation means, together with fractions containing the modulators (e.g., antagonists or blockers). The presence of a modulator is detected by monitoring a change in the response of the biosensor, e.g., by measuring changes in electrical properties of the biosensor (such as through patch clamp analysis).Type: GrantFiled: December 2, 1999Date of Patent: September 24, 2002Assignee: Cellectricon ABInventors: Owe Orwar, Kent Jardemark
-
Patent number: 6436640Abstract: DNA and RNA diagnostics based on mass spectrometry, e.g. Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight (MALDI-TOF) mass spectrometry, Electrospray (ES) mass spectrometry, Ion Cyclotron Resonance (ICR) mass spectrometry, Fourier Transform mass spectrometry, or combinations thereof, where fully or partially LNA modified DNA probes are used in order to enhance stability and resolution.Type: GrantFiled: March 18, 2000Date of Patent: August 20, 2002Assignee: Exiqon A/SInventors: Adrian Simmons, Clifford Smith
-
Patent number: 6432539Abstract: A phosphorus-containing polymer having phenolic units and an epoxy rein composition are provided. The epoxy resin composition suitably comprises an epoxy resin and a hardener, wherein the epoxy resin may be obtained by reacting the polymer with epihalohydrin, and the polymer may further act as the hardener.Type: GrantFiled: November 1, 1999Date of Patent: August 13, 2002Assignee: Chang Chun Plastics Co. Ltd.Inventors: Kuen-Yuan Hwang, Hong-Hsing Chen, An-Pang Tu, Ying-Ling Liu